Does enhanced recovery improve the survival rates of patients 3 years after undergoing surgery to remove a tumor in the colon?


Journal

International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899

Informations de publication

Date de publication:
Mar 2019
Historique:
accepted: 23 11 2018
pubmed: 12 12 2018
medline: 26 7 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

The advantages of enhanced recovery programs (ERP) after colorectal surgery for morbidity and length of stay are well known. On a longer term, evidence is much more limited. The aim of this study is to determine the impact of ERP on survival after 3 years of follow-up, following colorectal cancer surgery. All the patients undergoing resection for colorectal cancer between the years 2010 and 2014 were included. Patients were classified according to their compliance with the ERP (< 70 or ≥ 70%). Among the 206 patients included during the period, 129 were male (62.6%). The 3-year overall survival rate was 70.4% (145 patients) and relapse-free survival was 59.2% (122 patients). The survival after 3 years was influenced by the initial metastatic status (p < 0.0001), operative morbidity (p < 0.001), and the presence of peritumoral emboli (p = 0.006). However, the compliance with the ERP ≥ 70% did not influence overall survival (p = 0.63), nor relapse-free survival (p = 0.93). The same observations were found among the "at-risk" population (synchronous metastasis and postoperative complication). The ERP does not seem to influence the 3-year relapse-free survival after colorectal resection for cancer.

Identifiants

pubmed: 30536115
doi: 10.1007/s00384-018-3205-5
pii: 10.1007/s00384-018-3205-5
doi:

Types de publication

Journal Article

Langues

eng

Pagination

441-449

Références

Br J Surg. 2001 Sep;88(9):1221-7
pubmed: 11531871
Ann Chir. 2005 Feb;130(2):108-24
pubmed: 15737324
Arch Surg. 2005 Mar;140(3):278-83, discussion 284
pubmed: 15781793
Br J Surg. 2006 Sep;93(9):1115-22
pubmed: 16804870
Br J Surg. 2013 Jul;100(8):1108-14
pubmed: 23754650
Br J Surg. 2014 Feb;101(3):172-88
pubmed: 24469618
Anesth Analg. 2014 May;118(5):1052-61
pubmed: 24781574
World J Surg. 2015 Jun;39(6):1567-77
pubmed: 25651953
J Am Coll Surg. 2015 Apr;220(4):430-43
pubmed: 25797725
Eur J Cancer. 2015 May;51(8):925-34
pubmed: 25864037
World J Surg. 2016 Jul;40(7):1741-7
pubmed: 26913728
BMC Anesthesiol. 2016 Aug 03;16(1):55
pubmed: 27488470
J Visc Surg. 2016 Dec;153(6S):S41-S44
pubmed: 27789266
Ann Surg. 2017 Jan;265(1):68-79
pubmed: 28009729
Chirurgia (Bucur). 2016 Nov-Dec;111(6):476-480
pubmed: 28044948
JAMA Surg. 2017 Mar 1;152(3):292-298
pubmed: 28097305
Int J Colorectal Dis. 2017 May;32(5):675-681
pubmed: 28285365
Eur J Surg Oncol. 2017 Aug;43(8):1433-1439
pubmed: 28528188
World J Surg. 2018 Apr;42(4):953-964
pubmed: 28983734
Int J Colorectal Dis. 2018 Feb;33(2):231-234
pubmed: 29188453
J Surg Oncol. 2018 Mar;117(4):717-724
pubmed: 29355975
Br J Anaesth. 1997 May;78(5):606-17
pubmed: 9175983

Auteurs

P Viannay (P)

Department of Visceral and Endocrinal Surgery, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France.
Département de Médecine, UFR Santé d'Angers, Angers, France.

A Hamy (A)

Department of Visceral and Endocrinal Surgery, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France.
Département de Médecine, UFR Santé d'Angers, Angers, France.
EA HIFIH, Angers, France.

R Jaouen (R)

Department of Visceral and Endocrinal Surgery, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France.
Département de Médecine, UFR Santé d'Angers, Angers, France.

F X Caroli-Bosc (FX)

Département de Médecine, UFR Santé d'Angers, Angers, France.
EA HIFIH, Angers, France.
Department of Digestive and Liver Disease, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France.

C Luel (C)

Département de Médecine, UFR Santé d'Angers, Angers, France.

S Vasseur (S)

Département de Médecine, UFR Santé d'Angers, Angers, France.

M Levaillant (M)

Department of Biostatistics, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France.

J F Hamel (JF)

Département de Médecine, UFR Santé d'Angers, Angers, France.
Department of Biostatistics, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France.

Aurélien Venara (A)

Department of Visceral and Endocrinal Surgery, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France. auvenara@yahoo.fr.
Département de Médecine, UFR Santé d'Angers, Angers, France. auvenara@yahoo.fr.
EA HIFIH, Angers, France. auvenara@yahoo.fr.
UMR INSERM 1235, TENS, Université de Nantes, Rue Alexis Ricordeau, 44000, Nantes, France. auvenara@yahoo.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH